GSK Marks Second Lung Cancer Drug Approval This Year
On Tuesday, the Food and Drug Administration granted accelerated approval to GSK Plc.’s (NYSE:GSK) Nelkarmi (neladalkib) for locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The milestone marks the second lung cancer approval this year for the European drug giant. Regulators cleared the kinase inhibitor for patients who previously…
The Food and Drug Administration (FDA) has granted accelerated approval to GSK Plc.'s (NYSE:GSK) new lung cancer drug, Nelkarmi (neladalkib), for treating locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). This marks the second lung cancer approval for the European drug company in the same year.
The FDA's approval is based on the Phase 1/2 ALKOVE-1 trial, which showed significant and lasting results in patients who had previously received one ALK tyrosine kinase inhibitor (TKI) like alectinib or two or more ALK TKIs along with platinum-based chemotherapy in an unresectable locally advanced or metastatic setting.
Written by urgent.news from Benzinga's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.